<DOC>
	<DOCNO>NCT02672306</DOCNO>
	<brief_summary>The primary purpose study evaluate safety efficacy ( Human Umbilical Cord-Derived Mesenchymal Stem Cells ) UCMSCs patient Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>Safety Exploratory Efficacy Study UCMSCs Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Treatment , Parallel Assignment , Double Blind ( Subject , Outcomes Assessor ) , Randomized , Safety/ Efficacy Study Official Title : Multicenter , Randomized , Double-blind , Placebo Controlled Trial UCMSCs Subjects With Alzheimer 's Disease</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>A diagnosis probable AD Mixed Dementia accord criterion NINCDSADRDA History cognitive decline gradual onset progressive least 6 month MMSE score 3 20 , inclusive Home monitoring available supervision medication Voluntarily participate subject sign Inform Concent Subject positive test Human Immunodeficiency Virus ( HIV ) Subject undergo Magnetic Resonance Imaging ( MRI ) , compute tomography ( CT ) screen Subject psychological disease ( i.e . depression , schizophrenia , bipolar disorder , etc ) Subject cancer Subject dementia cause Alzheimer 's disease ( i.e . infection central nervous system , CreutzfeldtsJacob disease , severe head trauma , Pick 's disease , Huntington 's disease , Parkinson 's disease ) Subject severe white matter hyperintensities ( WMH ) ; Severe WMH define length deep white matter 25 mm long length periventricular capping/banding 10 mm longer Subject stroke 3 month Subject severe kidney failure ( 1.5 mg/dL serum creatinine ) Hemoglobin &lt; 9.5 g/dL men , &lt; 9.0 g/dL woman ; Total white blood count &lt; 3000/mm3 ; Total bilirubin ≥ 3 mg/dL Active hepatic renal disease Subject exclude subject selection process study Subject determine inappropriate investigator Subject allergic constitution History screening failure clinical trial neural stem cell A platelet count &lt; 150,000/mm3 ; Plasma prothrombin time ( PT ) ≥ 1.5 ; international normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) ≥ 1.5 x control value Participation another clinical trial within three month prior begin ( Week 0 ) clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>